Milestone Scientific Inc (MLSS) — 13F Filings Explorer (Q2 2026)

MLSS ranks #7395 out of 37505 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

31 institutions disclose a position in MLSS, but none treat it as a major bet — even Stonepine Capital Management, LLC, its most concentrated holder, allocates just 0.2% of its own portfolio to it.

State Street has added to its MLSS position for two straight quarters, increasing it by $46.8K to reach $85.0K today.

UBS Group AG has trimmed its MLSS position for two straight quarters, cutting it by $23.4K while still holding $2.8K.

MLSS reported a net loss of $5.7M in its latest fiscal year.

• Not yet profitable — net loss of $5.7M in the latest fiscal year
• Revenue grew 4.0% year over year
• Net income declined year over year, from -$4.7M to -$5.7M
• Operating cash flow was negative, using $2.9M in cash
• Current ratio of 1.81x — enough short-term assets to cover short-term liabilities
• Liabilities run 62.04x equity — a highly leveraged balance sheet worth noting